Otamixaban

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Otamixaban
Otamixaban.svg
Otamixaban 3D.png
Systematic (IUPAC) name
Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate
Clinical data
Legal status ?
Identifiers
CAS number 193153-04-7 N
ATC code None
PubChem CID 5496659
ChemSpider 4593439 YesY
UNII S173RED00L YesY
ChEMBL CHEMBL46618 YesY
Chemical data
Formula C25H26N4O4 
Mol. mass 446.498 g/mol
 N (what is this?)  (verify)

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor,[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.[2][3]

References[edit]

  1. ^ Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. doi:10.2174/092986707782023659. PMID 17979700. 
  2. ^ "AstraZeneca, Sanofi Cut Programs". Chemical & Engineering News (American Chemical Society) 91 (23): 17. June 10, 2013. "Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies." 
  3. ^ "Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs". RTT news. Retrieved 11 April 2014.